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to differences in change (ie, some items are more or less 
likely to detect differences between treatments).5,6 Which 
items should be included in the scales used in future trials 
of various treatments for depression? Should they be 
dependent on the treatments (eg, drugs, psychotherapies, 
neuromodulations), populations (eg, adolescents, adults, 
elderly people), or subtypes of depression examined? 
Good studies generate more questions than they answer. 
And good datasets allow us to ask important questions 
in rigorous ways. I thank Bondar and colleagues and the 
original investigators of TADS for their work, and welcome 
the increasingly common trend of data sharing.7
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Δ⁹-tetrahydrocannabinol: harmful even in low doses?
Cannabis is a substance that is shrouded in myth, 
paradox, and controversy. On the one hand, a host of 
literature indicates detrimental effects on areas such 
as mental health (eg, increased risk of schizophrenia 
and poorer prognosis among patients with psychiatric 
disorders who also use cannabis), risk of addiction, and 
psychosocial functioning.1–4 On the other hand, there 
has been an increase in public perception of cannabis as 
relatively harmless, as well as international movements 
to legalise cannabis for medicinal or recreational 
purposes.5 Of course, this does not necessarily constitute 
a paradox—benzodiazepines and opioids are also used 
both recreationally and medicinally, and with both 
positive (eg, reduction of pain or anxiety) and negative 
(eg, addiction or death) effects.
However, the controversy appears to run deeper in the 
case of cannabis, probably because of the counterculture 
that has existed around the substance for the past 
50 years. Cannabis is increasingly seen as harmless, 
perhaps because it is a natural product.5 Observed 
negative effects on mental health are, in this viewpoint, 
seen as stemming solely from self-medication. This 
controversy has also existed in the scientific community. 
Within a rather short time period, two systematic reviews 
were published in The Lancet.1,6 The first concluded 
that the associations between cannabis and psychosis 
were most likely explained by non-causal or selection 
mechanisms.6 The second concluded that, although 
causality between cannabis and psychosis was difficult to 
establish, there was ample reason to be cautious because 
evidence was pointing in this direction.1 Since then, 
much research has been published, and there appears 
to be a growing scientific consensus that cannabis does 
have a causal role in the development of psychosis. 
Indeed, the association appears to be bidirectional, so 
both hypotheses are probably correct.7,8 In some people, 
cannabis leads to incident psychosis, whereas in other 
people, psychosis leads to incident cannabis use.
This growing scientific consensus is not reflected in 
the mainstream public discourses, which have a major 
effect on the political agenda to decriminalise or legalise 
cannabis. It also appears that, in many places (eg, several 
US states), the first thing to be legalised is medicinal 
cannabis followed by increasing decriminalisation and 
sometimes complete legalisation of cannabis. It is thus 
of utmost importance that the public and politicians 
are informed of the most up-to-date evidence on 
cannabis. Adding to the state of this evidence is the 
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systematic review and meta-analysis by Guy Hindley 
and colleagues9 in The Lancet Psychiatry. The authors 
demonstrate that Δ⁹-tetrahydrocannabinol (THC) leads 
to an increase in total symptoms, which was assessed in 
nine studies, with ten independent samples, involving 
196 participants: standardised mean change in scores 
(assessed with the Brief Psychiatric Rating Scale and 
the Positive or Negative Syndrome Scale) 1·10 (95% CI 
0·92–1·28, p<0·0001). The effect sizes were also large 
for other symptoms (including general psychiatric 
symptoms), and were induced even with low doses 
of THC, somewhat similar to the doses often seen in 
medicinal cannabis, which we find extremely important 
and worrying. Moreover, the authors failed to find 
any clear evidence that concurrent administration of 
cannabidiol (CBD) reduced these symptoms. Indeed, 
such an ameliorating effect was observed in only one of 
four included studies. This finding is notable because CBD 
in particular is being touted as a potential wonder drug 
with antipsychotic, anxiolytic, and other properties.10 
Although it is quite possible that CBD will have some 
therapeutic applications (once proper randomised trials 
have been done), this supports suggestions that many 
of the initial reports and public discourses regarding the 
usefulness of both pure CBD and whole-plant-based 
extracts of cannabis might be somewhat exaggerated 
compared with what we can expect in clinical practice. 
Finally, although THC, alone or in combination with, 
for example, CBD might have a role in treating certain 
symptoms, caution should not be thrown to the wind. As 
Hindley and colleagues have clearly demonstrated, there 
are at least transient psychiatric symptoms associated 
with even relatively low doses of THC. Of course, this 
result should not be extrapolated as meaning that single 
doses of THC will eventually lead to schizophrenia or 
other severe disorders. However, it might be prudent 
to extrapolate and paraphrase the words of Moore and 
colleagues from their 2007 meta-analysis to apply to 
both recreational and medicinal use of THC-containing 
cannabis: “there is sufficient evidence to warn people 
that using THC could increase their risk of developing 
psychiatric symptoms or even a psychotic illness”.1
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Digital phenotyping: hype or hope?
In September, 2018, Thomas Insel speculated that, 
in 2050, psychiatrists will have realised that “the 
revolution in technology and information science will 
prove more consequential for global mental health,” 
compared with the developments in genomics and 
neuroscience.1 This is an astounding statement in itself, 
especially from somebody who advocated genomics 
and neuroscience2 in his former position as head of 
The National Institute of Mental Health. However, what 
exactly is meant by information science and why should 
it outpace neuroscience and genetics?
Digital phenotyping refers to the moment-to-moment 
quantification of human behaviour in everyday life using 
data from personal digital devices.3,4 This process will, 
according to Insel, overcome challenges in mental health 
by providing objective assessments of symptomatology 
